Responses observed in patients with and without previous exposure to other KRAS G12C inhib ...

Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety ...

BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell ...

A novel oral molecule significantly reduced inflammatory markers linked to development of arteriosclerotic cardiovascular ...

Patient- and physician-facing interventions together doubled the reductions in PPI use ...

Enanta is in a strong position to dominate the largely untapped RSV therapeutics market with a Phase III trial on the horizon ...

The firm is hoping to show that ODM-212 has anti-tumor activity and can prevent treatment resistance across multiple cancer indications.

The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors ...

Volatility is one of the things you’ll want to be prepared to address this season, depending on your nitrogen source. Nitrogen inhibitors, often referred to as stabilizers, are increasingly used by ...